Insights

What are the elements of innovative, effective medication adherence programs -- and how do they address the underlying causes of non-adherence?

Why do patients struggle with medication adherence even when they know it will help them? In part one of a two-part article series from Lash Group, discover how the most advanced patient support programs use behavioral science to unlock adherence.

Cell and gene therapies are currently at the forefront of scientific innovation. They hold great promise for patients suffering from a range of serious ailments.

The future of eBV is here. How manufacturers can use AI to help patients start life-changing therapies faster than ever.

We asked 100 physicians to share their perspectives on biosimilar utilization, cost savings, and adoption barriers. See what they said and what it means for the market and manufacturers.

For Angela, a nurse navigator with Lash Group, every phone call is an opportunity to help a cancer patient, and sometimes solve problems they didn't even know they had.

Executive Q&A: How to make the annual benefits reverification process as smooth as possible for patients and key stakeholders.

How do nurses make a difference when it comes to patient-centric adherence programs? A Lash Group nurse shares how she offers personal support for rare disease patients.

Executive Q&A: best practices for a patient support program launch.

Lash Group's nurse educators offer empathy, experience and expertise to help patients navigate the complexities of today's specialty therapies. Learn how they add critical value to adherence programs.

The growth of biosimilars presents a significant opportunity to reduce the cost of care and provide patients with greater access to affordable treatments. Our experts assess the current state and future of the biosimilars market.

How are biosimilar manufacturers approaching patients, providers and payers? What can they do to differentiate? Xcenda shares insight from our field programs.

An animated, immersive biosimilar market snapshot with actionable insight for manufacturers.

We asked 100 physicians to share their perspectives on biosimilar utilization, cost savings, and adoption barriers. See what they said and what it means for the market and manufacturers.

Innovative therapies make innovative patient services essential. Learn how Lash Group helped one manufacturer improve speed and access to therapy with an electronic provider portal for benefit verification and prior authorization.

What are the elements of innovative, effective medication adherence programs -- and how do they address the underlying causes of non-adherence?

In this digital age, how can pharmaceutical manufacturers leverage innovative tools to prove their product's value proposition and overcome market access challenges?

Two experts in health economics and patient support team up to offer insight on how manufacturers can prepare for the impact of copay accumulators.

How adherence solutions are evolving -- with some high-tech help. Originally published on FiercePharma.com.

Phase II of DSCSA requires interoperable systems for the electronic tracking of product through the supply chain. Is pharma prepared? Learn what stakeholders need to know and do know to prepare for 2023.

Executive Q&A: The market trends and technology solutions impacting medication adherence today.

Download this new white paper from IHOC - Coordinated Care: The Value of Patient and Provider Satisfaction within Health System Specialty Pharmacies - to learn the key insights about the role HSSPs play in improving the patient experience and why patient and provider satisfaction are important data points for both payers and manufacturers to consider when deciding to include HSSPs in their networks.

Executive Q&A: How shifting coverage for some drugs from Medicare Part B to Part D could impact access and affordability for patients.

What does Medicare claims data reveal about physician-administered drugs? An Xcenda survey reveals whether physicians choose treatment based on how much they're reimbursed.

Why is accreditation important for patient support program providers?

What are the pitfalls of historic approaches to adherence? Learn how leading solutions combine both measurement and engagement for real results.

Open enrollment for Health Insurance Marketplace plans is here. Do PAP patients know their coverage options?

How leading patient support providers combine measurement with engagement to improve adherence.

The evolving needs of the patient and historic approaches to non-adherence.

How can FTZs help with commercialization success? What should manufacturers consider when evaluating a FTZ and 3PL partner?

What are FTZs and why should pharma use them?

Much of the complexity of the cell and gene supply chain comes from how dependent the commercialization phase is on the clinical phase. What does integration look like, and how can the right logistics partner help?

Patients face a growing number of barriers that can impede medication access and adherence. How can manufacturers help address these hurdles?

How third-party logistics (3PL) solutions can help cell and gene therapy manufacturers manage the financial aspects of launching new therapies.

An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.

An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.

How manufacturers can benefit from provider-led care coordination to improve patient outcomes.

How is manufacturer thinking around channel strategy changing for oral oncolytics?

How drug manufacturers, health systems and payers can collaborate more closely in the new world of patient-centered care.

What challenges does the increased demand for care coordination create for health system specialty pharmacies and what opportunities does it present for demonstrating value?

How can manufacturers approach reimbursement and patient support for cell and gene therapies and other medical innovations?

What information do payers and providers want from pharma?

How can data-driven service design improve patient support programs and outcomes?

What should biosimilar manufacturers focus on for commercialization success?

What does the future of benefit verification look like for manufacturer patient support programs?

How are payers thinking about apps, wearables and other digital health technologies?

Understanding the unique considerations for reimbursement in the Canadian pharmaceutical market.

Rich Tremonte on the current healthcare landscape, the role of the wholesaler and how the new organizational structure at AmerisourceBergen brings out the best in both.

In supply chain decisions, a wholly new type of product demands a wholly new definition for supply chain expertise and effective support.

Learn what it takes to design an effective commercialization strategy and execute an integrated solution when the patient is in the supply chain.

Learn the unintended consequences of channel strategy decisions and the impact on patients and providers.

An interview with Matt George, patient advocate and survivor of paroxysmal nocturnal haemoglobinuria (PNH), a debilitating, rare and life-threatening disorder.

Successful commercialization demands that manufacturers address three critical areas of opportunity — evidence, access and adherence.